Profound Medical (Nasdaq: PROF) announced today that it has finalized a co-sales and co-marketing agreement with Siemens Healthineers. This partnership aims to introduce an MRI-guided prostate therapy solution to the market. The integrated offering combines Profound’s TULSA-PRO system and consumables with Siemens Healthineers’ Magnetom Free.Max MR scanner. This agreement builds on a collaboration unveiled earlier this year, focusing on integrating TULSA-PRO and Magnetom Free.Max technologies.
The TULSA-PRO utilizes Profound’s transurethral ultrasound ablation (TULSA) method, leveraging real-time MR imaging to precisely target and ablate prostate tissue utilizing sound absorption technology. This system is designed to allow surgeons to conduct comprehensive or partial ablation on patients with varying levels of prostate cancer, as well as manage benign prostatic hyperplasia (BPH). It caters to prostate cancer patients under active observation seeking symptom relief from BPH.
Siemens’ Magnetom Free.Max enhances the scope of MR clinical applications and offers the distinct benefits inherent in a mid-field MR scanner. It also accommodates larger and/or claustrophobic patients, improving their scanning experience.
Pending the completion of compatibility testing between TULSA-PRO and Magnetom Free.Max, the companies forecast a 2025 launch for their comprehensive “total prostate solution.”
Insights from Siemens Healthineers and Profound Medical Representatives:
Donald Hardie, Global Marketing & Sales Head for Magnetic Resonance at Siemens Healthineers, remarked, “We are thrilled to showcase our shared vision with Profound for an MRI-guided prostate therapy solution at the ‘PRO-TALK Live!’ event set for September 2024. This solution is a fusion of our leading diagnostic and interventional MR technologies. Magnetom Free.Max is already transforming MR access, reaching previously underserved locations such as orthopedic centers and rural hospitals, addressing the vital need for diagnostic MR imagery. We eagerly anticipate collaborating with Profound to increase access to prostate disease interventions with TULSA.”
Arun Menawat, CEO and Chair of Profound Medical, stated, “Our collaborative agreement with Siemens Healthineers aligns with our mission to ensure our technology is widely accessible to urologists and patients dealing with prostate disease. This alignment is particularly timely as the CMS recognizes the value of the TULSA procedure, assigning it to Urology APC Level 7. The Magnetom Free.Max provides image quality similar to larger 1.5T scanners, making the newly branded TULSA+ program suitable for ASCs that require advanced MR imaging for orthopedic work. These centers can now apply the same investment for urological treatment of prostate cancer or BPH. The positive outcomes from the Final Rules present a compelling business case for technology adoption, extending access from hospital surgical departments to ASCs and even medical offices.”